Health Care · Pharmaceutical Preparations · Nasdaq · CIK 2022626 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $6.41Day +0.16%Mkt cap $349M1Y −54.1%Off 52W high −81.0%Vol (1Y) 92.8%
Daily closing price, split-adjusted to the current basis; 1.7y shown of 439 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest6.6% of sh out |
| Days to cover8.2d |
| 13F net flow (QoQ)−1.57% |
| Top-10 13F concentration62.6% |
| Next report (est.)2026-08-12 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$3.3M |
| Earnings (TTM)-$156.8M |
| ROE−35.4% |
| Net margin−5026.0% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−76.4% |
| 1Y−54.1% |
| Since incept. (ann.)−49.7% |
Total return through 2026-07-29 · series begins 2024-10-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)92.8% |
| Ann. volatility (3Y)91.6% |
| Sharpe (1Y)−0.36 |
| Sharpe (3Y)−0.27 |
| Max drawdown (1Y)−81.8% |
| Max drawdown (3Y)−81.8% |
| Beta (3Y vs SPY)1.26 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| FMR LLC | 8.1M | $73M | 14.89% | +7.8% |
| ORBIMED ADVISORS LLC | 5.7M | $51M | 10.46% | +0.0% |
| BlackRock, Inc. | 3.4M | $30M | 6.19% | +0.8% |
| Decheng Capital LLC | 2.7M | $25M | 5.01% | −13.3% |
| ENAVATE SCIENCES GP, LLC | 2.5M | $22M | 4.52% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.9M | $17M | 3.44% | new |
| Y-Intercept (Hong Kong) Ltd | 1.0M | $9M | 1.84% | +2049.2% |
| FEDERATED HERMES, INC. | 979,758 | $9M | 1.80% | +203169.3% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-13 | −$0.75 | — | $1.0M | +82.7% |
| 2025-12-31 | 2026-03-26 | — | — | $668,000 | +9.0% |
| 2025-09-30 | 2025-11-05 | −$0.63 | — | $683,000 | +12.5% |
| 2025-06-30 | 2025-08-06 | −$0.74 | — | $937,000 | +83.7% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-12 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
